167 related articles for article (PubMed ID: 31423748)
1. Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
Hinrichs GR; Weyer K; Friis UG; Svenningsen P; Lund IK; Nielsen R; Mollet G; Antignac C; Bistrup C; Jensen BL; Birn H
Acta Physiol (Oxf); 2019 Dec; 227(4):e13362. PubMed ID: 31423748
[TBL] [Abstract][Full Text] [Related]
2. Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Stæhr M; Buhl KB; Andersen RF; Svenningsen P; Nielsen F; Hinrichs GR; Bistrup C; Jensen BL
Am J Physiol Renal Physiol; 2015 Aug; 309(3):F235-41. PubMed ID: 25972510
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
Bohnert BN; Daiminger S; Wörn M; Sure F; Staudner T; Ilyaskin AV; Batbouta F; Janessa A; Schneider JC; Essigke D; Kanse S; Haerteis S; Korbmacher C; Artunc F
Acta Physiol (Oxf); 2019 Dec; 227(4):e13286. PubMed ID: 31006168
[TBL] [Abstract][Full Text] [Related]
4. Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria.
Isaksson GL; Hinrichs GR; Andersen H; Bach ML; Weyer K; Zachar R; Henriksen JE; Madsen K; Lund IK; Mollet G; Bistrup C; Birn H; Jensen BL; Palarasah Y
J Am Soc Nephrol; 2024 Apr; 35(4):410-425. PubMed ID: 38254266
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome.
Larionov A; Dahlke E; Kunke M; Zanon Rodriguez L; Schiessl IM; Magnin JL; Kern U; Alli AA; Mollet G; Schilling O; Castrop H; Theilig F
J Cell Mol Med; 2019 Oct; 23(10):6543-6553. PubMed ID: 31368174
[TBL] [Abstract][Full Text] [Related]
6. Plasmin in nephrotic urine activates the epithelial sodium channel.
Svenningsen P; Bistrup C; Friis UG; Bertog M; Haerteis S; Krueger B; Stubbe J; Jensen ON; Thiesson HC; Uhrenholt TR; Jespersen B; Jensen BL; Korbmacher C; Skøtt O
J Am Soc Nephrol; 2009 Feb; 20(2):299-310. PubMed ID: 19073825
[TBL] [Abstract][Full Text] [Related]
7. Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells.
Andersen H; Friis UG; Hansen PB; Svenningsen P; Henriksen JE; Jensen BL
Nephrol Dial Transplant; 2015 May; 30(5):781-9. PubMed ID: 25609736
[TBL] [Abstract][Full Text] [Related]
8. Amiloride: the "new" renal tonic?
Warnock DG
Am J Physiol Renal Physiol; 2015 Sep; 309(5):F429-30. PubMed ID: 26084931
[No Abstract] [Full Text] [Related]
9. Mechanisms of renal NaCl retention in proteinuric disease.
Svenningsen P; Friis UG; Versland JB; Buhl KB; Møller Frederiksen B; Andersen H; Zachar RM; Bistrup C; Skøtt O; Jørgensen JS; Andersen RF; Jensen BL
Acta Physiol (Oxf); 2013 Mar; 207(3):536-45. PubMed ID: 23216619
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen deficiency does not prevent sodium retention in a genetic mouse model of experimental nephrotic syndrome.
Xiao M; Bohnert BN; Aypek H; Kretz O; Grahammer F; Aukschun U; Wörn M; Janessa A; Essigke D; Daniel C; Amann K; Huber TB; Plow EF; Birkenfeld AL; Artunc F
Acta Physiol (Oxf); 2021 Jan; 231(1):e13512. PubMed ID: 32455507
[TBL] [Abstract][Full Text] [Related]
11. Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC.
Andersen RF; Buhl KB; Jensen BL; Svenningsen P; Friis UG; Jespersen B; Rittig S
Pediatr Nephrol; 2013 Aug; 28(8):1227-34. PubMed ID: 23503750
[TBL] [Abstract][Full Text] [Related]
12. Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Oxlund CS; Buhl KB; Jacobsen IA; Hansen MR; Gram J; Henriksen JE; Schousboe K; Tarnow L; Jensen BL
J Am Soc Hypertens; 2014 Dec; 8(12):872-81. PubMed ID: 25492830
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of sodium retention in nephrotic syndrome.
Hinrichs GR; Jensen BL; Svenningsen P
Curr Opin Nephrol Hypertens; 2020 Mar; 29(2):207-212. PubMed ID: 31789848
[TBL] [Abstract][Full Text] [Related]
14. Proteinuric diseases with sodium retention: Is plasmin the link?
Svenningsen P; Skøtt O; Jensen BL
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):117-24. PubMed ID: 21466573
[TBL] [Abstract][Full Text] [Related]
15. Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.
Andersen H; Hansen PB; Bistrup C; Nielsen F; Henriksen JE; Jensen BL
J Hypertens; 2016 Aug; 34(8):1621-9. PubMed ID: 27214087
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Andersen H; Hansen MH; Buhl KB; Stæhr M; Friis UG; Enggaard C; Supramaniyam S; Lund IK; Svenningsen P; Hansen PBL; Jensen BL
J Am Heart Assoc; 2020 Dec; 9(23):e016387. PubMed ID: 33215566
[TBL] [Abstract][Full Text] [Related]
17. Albuminuria in kidney transplant recipients is associated with increased urinary serine proteases and activation of the epithelial sodium channel.
Hinrichs GR; Michelsen JS; Zachar R; Friis UG; Svenningsen P; Birn H; Bistrup C; Jensen BL
Am J Physiol Renal Physiol; 2018 Jul; 315(1):F151-F160. PubMed ID: 29363322
[TBL] [Abstract][Full Text] [Related]
18. Amiloride evokes significant natriuresis and weight loss in kidney transplant recipients with and without albuminuria.
Hinrichs GR; Nielsen JR; Birn H; Bistrup C; Jensen BL
Am J Physiol Renal Physiol; 2023 Oct; 325(4):F426-F435. PubMed ID: 37560772
[TBL] [Abstract][Full Text] [Related]
19. Association of Urinary Plasminogen-Plasmin with Edema and Epithelial Sodium Channel Activation in Patients with Nephrotic Syndrome.
Chen JL; Wang L; Yao XM; Zang YJ; Wang Y; Li ZJ; Pearce D; Wang H
Am J Nephrol; 2019; 50(2):92-104. PubMed ID: 31269481
[TBL] [Abstract][Full Text] [Related]
20. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
Nakhoul F; Ramadan R; Khankin E; Yaccob A; Kositch Z; Lewin M; Assady S; Abassi Z
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F880-90. PubMed ID: 15942045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
